Therapy with clopidogrel based on CYP2C19 genotype

dc.contributor.author	Dogot, Marta
dc.contributor.author	Popa, Ana
dc.date.accessioned	2020-08-18T12:09:12Z
dc.date.available	2020-08-18T12:09:12Z
dc.date.issued	2018
dc.identifier.citation	DOGOT, Marta, POPA, Ana. Therapy with clopidogrel based on CYP2C19 genotype. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 99-100.	en_US
dc.identifier.uri	https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf
dc.identifier.uri	http://repository.usmf.md/handle/20.500.12710/11416
dc.description	Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova	en_US
dc.description.abstract	Introduction. Combined therapy, clopidogrel plus aspirin, prevents secondary thrombotic in acute coronary syndromes (ACS), after percutaneous coronary interventions (PCI) with placement of a coronary artery stent. Clopidogrel is activated in the liver by cytochrome P450 enzymes. CYP2C19 is the principal enzyme. The most common loss-of-function variant is CYP2C19*2. This contributes to the decrease in the active metabolite of clopidogrel in the blood and reduce the effectiveness of clopidogrel therapy.	en_US
dc.language.iso	en	en_US
dc.publisher	MedEspera	en_US
dc.subject	CYP2C19 genotype	en_US
dc.subject	clopidogrel	en_US
dc.title	Therapy with clopidogrel based on CYP2C19 genotype	en_US
dc.type	Article	en_US